The TOPaZ Trial - Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
TOPaZ is a randomised open-label clinical trial for people with Osteogenesis Imperfecta (OI).
The study aims to investigate whether a two-year spell of treatment with a drug called Teriparatide (TPTD) followed by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with Osteogenesis Imperfecta.
About the Trial
TOPaZ is a non-commercial trial sponsored by a partnership of the University of Edinburgh and NHS Lothian called ACCORD and funded by the UK National Institute for Health Research (NIHR).
Get Involved
If you have Osteogenesis Imperfecta (brittle bone disease) and you are aged 18 years or over you may be eligible to take part in the TOPaZ trial.
News and Updates
Check here for further information and news about the progress of the TOPaZ Trial
Our Centres and Partners
TOPaZ involves a collaboration of key partners and over 25 recruiting centres across the UK, Ireland, France, the Netherlands and Denmark.
What is Osteogenesis Imperfecta?
Osteogenesis Imperfecta (OI) is a rare genetic condition present from birth and is frequently called ‘brittle bone disease’.
Database for Research Teams
Link to trial data capture system for use by participating research teams